Published in Cancer Chemother Pharmacol on January 01, 1999
Crystal structure of 9-amino-N-[2-(4-morpholinyl)ethyl]-4-acridinecarboxamide bound to d(CGTACG)2: implications for structure-activity relationships of acridinecarboxamide topoisomerase poisons. Nucleic Acids Res (2002) 1.23
Unusual intercalation of acridin-9-ylthiourea into the 5'-GA/TC DNA base step from the minor groove: implications for the covalent DNA adduct profile of a novel platinum-intercalator conjugate. Nucleic Acids Res (2003) 0.92
Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide. Invest New Drugs (2010) 0.87
A novel form of intercalation involving four DNA duplexes in an acridine-4-carboxamide complex of d(CGTACG)(2). Nucleic Acids Res (2000) 0.86
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs (2003) 0.81
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049. Cancer Chemother Pharmacol (2008) 0.80
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis (1995) 2.42
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) J Med Chem (1994) 1.93
A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem J (1937) 1.89
A steady-state and pre-steady-state kinetic analysis of the NTPase activity associated with the hepatitis C virus NS3 helicase domain. J Biol Chem (1996) 1.71
Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst (1990) 1.57
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem (1991) 1.51
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Papulacandin B: an inhibitor of glucan synthesis in yeast spheroplasts. Eur J Biochem (1979) 1.49
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 1.49
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. Br J Cancer (1991) 1.42
Structure of a mammalian serine tRNA. Nature (1968) 1.41
Direct evidence for carbanions and covalent N 5 -flavin-carbanion adducts as catalytic intermediates in the oxidation of nitroethane by D-amino acid oxidase. J Biol Chem (1973) 1.40
Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol (1990) 1.39
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres. Aust N Z J Med (1995) 1.38
Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization. Lab Invest (1993) 1.38
The Legs for Life screening for peripheral vascular disease: compliance with physician recommendations in moderate- and high-risk assessed patients. J Vasc Interv Radiol (2001) 1.38
Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol (1987) 1.33
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep (1983) 1.32
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer (2002) 1.32
Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res (1991) 1.30
Quenching of DNA-ethidium fluorescence by amsacrine and other antitumor agents: a possible electron-transfer effect. Biochemistry (1984) 1.29
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1995) 1.26
Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst (1988) 1.26
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res (1999) 1.24
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res (1999) 1.22
Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother Pharmacol (2000) 1.22
Nonintercalative DNA-binding antitumour compounds. Mol Cell Biochem (1982) 1.21
The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Res (1978) 1.20
Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol (1987) 1.20
Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer (2000) 1.18
Substrate specificity of adenine-specific transfer RNA methylase in normal and leukemic tissues. Eur J Biochem (1968) 1.17
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer (1998) 1.16
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer (2003) 1.15
Potential antitumor agents. 59. Structure-activity relationships for 2-phenylbenzimidazole-4-carboxamides, a new class of "minimal" DNA-intercalating agents which may not act via topoisomerase II. J Med Chem (1990) 1.12
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res (1994) 1.11
Existence of an extended series of antitumor compounds which bind to deoxyribonucleic acid by nonintercalative means. Biochemistry (1980) 1.10
Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Auckland Breast Cancer Study Group. Int J Cancer (1996) 1.09
Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. Mol Pharmacol (1981) 1.09
Survival of women with node negative breast cancer in the Auckland region. N Z Med J (1996) 1.08
Mechanism of oxidation of nitroethane by glucose oxidase. J Biol Chem (1977) 1.07
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. J Med Chem (1978) 1.07
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res (1994) 1.06
Nitro analogues of citrate and isocitrate as transition-state analogues for aconitase. Biochemistry (1980) 1.05
Kinetic analysis of the effects of mutagenesis of W501 and V432 of the hepatitis C virus NS3 helicase domain on ATPase and strand-separating activity. Biochemistry (2000) 1.05
Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J Med Chem (1987) 1.05
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer (2002) 1.05
Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J Med Chem (1988) 1.04
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet (2001) 1.03
Nitromethane. A novel substrate for D-amino acid oxidase. J Biol Chem (1972) 1.03
A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem (1984) 1.02
Two-step binding mechanism for HIV protease inhibitors. Biochemistry (1992) 1.02
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. J Med Chem (1989) 1.02
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol (1999) 1.02
Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer (2001) 1.00
Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res (1990) 1.00
Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer (2001) 1.00
Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol (1983) 0.99
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol (1991) 0.99
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res (2001) 0.98
In vitro methylation of yeast serine transfer ribonucleic acid. Biochemistry (1970) 0.98
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays. Eur J Cancer (1994) 0.98
Potential antitumor agents. 44. Synthesis and antitumor activity of new classes of diacridines: importance of linker chain rigidity for DNA binding kinetics and biological activity. J Med Chem (1985) 0.98
Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide. Br J Cancer (1992) 0.97
Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer (2004) 0.97
Comparison of radioimmunoassay and enzyme-linked immunoassay for the measurement of progestogen in equine plasma and milk. Vet Rec (1987) 0.97
Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res (1997) 0.97
Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem (1987) 0.97
The recovery of immune responsiveness after treatment with cyclophosphamide. Int Arch Allergy Appl Immunol (1971) 0.96
Nitroalkanes as reductive substrates for flavoprotein oxidases. Z Naturforsch B (1972) 0.96
A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol (1986) 0.96
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer (1992) 0.95
Herpes and human ribonucleotide reductases. Inhibition by 2-acetylpyridine 5-[(2-chloroanilino)-thiocarbonyl]-thiocarbonohydrazone (348U87). Biochem Pharmacol (1991) 0.95
Potential antitumor agents. 57. 2-Phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. J Med Chem (1989) 0.95
A comparison of 1-methyladenine-containing sequences in transfer ribonucleic acid from yeast and from rat liver. Biochemistry (1969) 0.95
Enhancement of in vitro cytotoxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol (1988) 0.95
3-Carbanionic substrate analogues bind very tightly to fumarase and aspartase. J Biol Chem (1980) 0.95
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys (1994) 0.94
Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst (1990) 0.94
Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int (1999) 0.94
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep (1985) 0.93
From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer (1996) 0.93
Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. J Med Chem (1984) 0.93
Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst (1992) 0.93
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives. J Med Chem (2001) 0.93
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. Eur J Cancer Clin Oncol (1986) 0.93
Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA. Bioorg Med Chem (1999) 0.92
Mechanistic features of the D-amino acid oxidase reaction studied by double stopped flow spectrophotometry. J Biol Chem (1977) 0.92
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology (1994) 0.91
Risk factors for early hospital readmission after cardiac operations. J Thorac Cardiovasc Surg (2001) 0.91
The specificity of transfer ribonucleic acid methylases from rat liver. Biochemistry (1968) 0.91
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol (1991) 0.91